AYTU BioPharma
AYTU
13 hedge funds and large institutions have $6.04M invested in AYTU BioPharma in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
55% more capital invested
Capital invested by funds: $3.9M → $6.04M (+$2.14M)
44% more funds holding
Funds holding: 9 → 13 (+4)
0% more ownership
Funds ownership: 0.09% → 0.1% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WC
Wexford Capital
West Palm Beach,
Florida
|
+$1.18M |
| 2 |
SC
Searle & Co
Greenwich,
Connecticut
|
+$355K |
| 3 |
Bank of New York Mellon
New York
|
+$75.8K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$56K |
| 5 |
BlackRock
New York
|
+$36.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$72K |
| 2 |
VF
Virtu Financial
New York
|
-$30K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$8.77K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $3.78M | – | – | – |
|
|
WC
2
Wexford Capital
West Palm Beach,
Florida
| $1.34M | +$1.18M | +3,091 | +690% |
|
|
SC
3
Searle & Co
Greenwich,
Connecticut
| $380K | +$355K | +931 | +1,241% |
|
4
Vanguard Group
Malvern,
Pennsylvania
| $180K | – | – | – |
|
5
Geode Capital Management
Boston,
Massachusetts
| $123K | +$20.6K | +54 | +20% |
|
|
6
Bank of New York Mellon
New York
| $75K | +$75.8K | +199 | New |
|
|
7
Bank of America
Charlotte,
North Carolina
| $56K | +$56K | +147 | New |
|
|
8
BlackRock
New York
| $36K | +$36.2K | +95 | New |
|
|
ARTA
9
A.R.T. Advisors
New York
| $23K | +$23.2K | +61 | New |
|
10
JP Morgan Chase
New York
| $22K | +$23.6K | +62 | New |
|
11
Northern Trust
Chicago,
Illinois
| $20K | – | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| $8K | -$8.77K | -23 | -51% |
|
|
TRCT
13
Tower Research Capital (TRC)
New York
| $2K | +$1.52K | +4 | New |
|
|
14
Acadian Asset Management
Boston,
Massachusetts
| – | -$72K | -216 | Closed |
|
|
VF
15
Virtu Financial
New York
| – | -$30K | -89 | Closed |
|
AYTU Hedge Fund Activity: Q2 2019 in Review
13 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q2 2019, worth a combined $6.04M — up 55% from $3.9M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AYTU positions and 2 closed out — a net gain of 4 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Wexford Capital, adding an estimated $1.18M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $72K sold.
- 13 institutional investors held AYTU BioPharma (AYTU) as of Q2 2019, up from 9 in Q1 2019.
- Funds reported $6.04M of AYTU BioPharma stock for Q2 2019, up 55% quarter-over-quarter.
- 6 funds opened new AYTU BioPharma positions in Q2 2019 and 2 closed out, a net change of +4 holders.
- The largest AYTU BioPharma buyer in Q2 2019 was Wexford Capital, an estimated $1.18M added.
- The largest AYTU BioPharma seller in Q2 2019 was Acadian Asset Management, an estimated $72K sold.
Based on aggregated 13F filings for Q2 2019.